{"id":"W4410140459","doi":"10.1182/bloodadvances.2025016229","title":"Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre","funders":"Genentech; Swedish Orphan Biovitrum; Servier; Astellas Pharma; Incyte; bluebird bio; Agios Pharmaceuticals; Astex Pharmaceuticals; Celgene; Gilead Sciences; Syndax Pharmaceuticals; BeiGene; Daiichi Sankyo Europe; Sanofi; Pfizer; Amgen","keywords":"Azacitidine; Placebo; Medicine; Internal medicine; Oncology; Clinical endpoint; Gastroenterology; Randomized controlled trial; Biology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001569994,0.001221057,0.001602975,0.000234043,0.0004072785,0.0008386356,0.0007466641,0.001029035,0.005326915],"category_scores_gemma":[0.0009769738,0.0003724445,0.001112801,0.0002401979,0.0005520097,0.0004332995,0.0002683206,0.002118278,0.0008614394],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005576975,"about_ca_system_score_gemma":0.001029078,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005004997,"about_ca_topic_score_gemma":0.001754281,"domain_scores_codex":[0.9996918,0.0001830324,0.00001804767,0.00003781671,0.00003180055,0.00003748454],"domain_scores_gemma":[0.9992643,0.0001378383,0.0001611838,0.00004489755,0.00006724525,0.0003245016],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8932223,0.01414398,0.004247366,0.0008115912,0.001158718,0.0002041516,0.0001388121,0.0009715517,0.03647251,0.0004031675,0.005812429,0.04241341],"study_design_scores_gemma":[0.8211753,0.1612496,0.00838655,0.00006937791,0.0006812201,0.0002315104,0.00004326414,0.0005007582,0.003323943,0.0002206712,0.004096669,0.00002111458],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9836065,0.004624506,0.000767172,0.0009519553,0.0002615721,0.003204168,0.003404795,0.0001096701,0.003069704],"genre_scores_gemma":[0.979853,0.002955997,0.002242834,0.00119096,0.0003183771,0.004175143,0.004561461,0.00004267315,0.004659506],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005326915,"threshold_uncertainty_score":0.01782036,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01056674117436585,"score_gpt":0.3171685288221179,"score_spread":0.306601787647752,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}